Epistaxis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Amir Bagheri (talk | contribs) No edit summary |
Amir Bagheri (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Epistaxis}} | {{Epistaxis}} | ||
{{CMG}} ; '''Associate Editor(s)-in-Chief''':[[User:Amir Bagheri|Amir Behzad Bagheri, M.D.]] | |||
<br /> | <br /> | ||
== Overview == | ==Overview== | ||
Most of the time no action is needed to stop epistaxis. In active bleeding nasal compression is the first line to stop bleeding. If bleeding continues there are other options like cautery and some vasoconstrictive agents like [[oxymetazoline]] or [[phenylephrine]] to control bleeding. | Most of the time no action is needed to stop epistaxis. In active bleeding nasal compression is the first line to stop bleeding. If bleeding continues there are other options like cautery and some vasoconstrictive agents like [[oxymetazoline]] or [[phenylephrine]] to control bleeding. | ||
==Medical Therapy== | ==Medical Therapy== | ||
* General management of patients is important. Stabilizing the patient and treating the specific cause is the basis of management.<ref name="TunkelAnne2020">{{cite journal|last1=Tunkel|first1=David E.|last2=Anne|first2=Samantha|last3=Payne|first3=Spencer C.|last4=Ishman|first4=Stacey L.|last5=Rosenfeld|first5=Richard M.|last6=Abramson|first6=Peter J.|last7=Alikhaani|first7=Jacqueline D.|last8=Benoit|first8=Margo McKenna|last9=Bercovitz|first9=Rachel S.|last10=Brown|first10=Michael D.|last11=Chernobilsky|first11=Boris|last12=Feldstein|first12=David A.|last13=Hackell|first13=Jesse M.|last14=Holbrook|first14=Eric H.|last15=Holdsworth|first15=Sarah M.|last16=Lin|first16=Kenneth W.|last17=Lind|first17=Meredith Merz|last18=Poetker|first18=David M.|last19=Riley|first19=Charles A.|last20=Schneider|first20=John S.|last21=Seidman|first21=Michael D.|last22=Vadlamudi|first22=Venu|last23=Valdez|first23=Tulio A.|last24=Nnacheta|first24=Lorraine C.|last25=Monjur|first25=Taskin M.|title=Clinical Practice Guideline: Nosebleed (Epistaxis)|journal=Otolaryngology–Head and Neck Surgery|volume=162|issue=1_suppl|year=2020|pages=S1–S38|issn=0194-5998|doi=10.1177/0194599819890327}}</ref> <ref name="KremplNoorily2016">{{cite journal|last1=Krempl|first1=Greg A.|last2=Noorily|first2=Allen D.|title=Use of Oxymetazoline in the Management of Epistaxis|journal=Annals of Otology, Rhinology & Laryngology|volume=104|issue=9|year=2016|pages=704–706|issn=0003-4894|doi=10.1177/000348949510400906}}</ref><ref name="MontastrucMontastruc2014">{{cite journal|last1=Montastruc|first1=François|last2=Montastruc|first2=Guillaume|last3=Taudou|first3=Marie-Josée|last4=Olivier-Abbal|first4=Pascale|last5=Montastruc|first5=Jean-Louis|last6=Bondon-Guitton|first6=Emmanuelle|title=Acute Coronary Syndrome After Nasal Spray of Oxymetazoline|journal=Chest|volume=146|issue=6|year=2014|pages=e214–e215|issn=00123692|doi=10.1378/chest.14-1873}}</ref> | |||
* <br />At first [[Airway]] , [[breathing]] and [[circulation]] should be evaluated. | |||
If nasal bleeding is active and nasal compression couldn't stop [[bleeding]], there are the following medical options: | |||
* '''[[Vasoconstrictors]]''' (Use with caution in children and patients with [[glaucoma]], [[Hypertension|HTN]], [[peripheral vasoconstriction]], [[Cardiac disease|cardiac diseases]] and [[cerebrovascular]] problems): | |||
** Preferred regimen (1): [[Oxymetazoline]] 0.05% [[intranasal]] [[spray]]. In children <6 years just with [[physicians]] suggestion. | |||
** Alternative regimen (1): [[Phenylephrine]] 0.25% [[intranasal spray]]. In children ≥2 years Phenylephrine 0.125% nasal solution can be used. | |||
** Alternative regimen (2): [[Epinephrine]] 1:100,000 with [[Lidocaine]] 1% (Topical ). | |||
* '''[[Antifibrinolytic]]''': | |||
** Preferred regimen (1): [[Tranexamic acid]] ([[Tranexamic acid|TXA]]) (Topical ).<br /> | |||
* '''[[Chemical]] [[cauterization]]''' ( At first [[anesthesia]] [[bleeding]] site and limit nasal [[cautery]] to site''':''' | |||
** Preferred regimen (1): [[Silver nitrate]] 25%-75% | |||
** Alternative regimen (1): [[Chromic acid]] | |||
** Alternative regimen (2): [[Trichloroacetic acid]] | |||
* Some [[Medicine|medicines]] are used to prevent [[epistaxis]]: | |||
** '''[[Emollient]] [[Cream (pharmaceutical)|creams]] :''' Continues using of topical [[emollient]] [[Cream (pharmaceutical)|creams]] is useful to prevent [[epistaxis]]. | |||
** '''[[Ointment|Ointments]] :''' Continues using of topical [[Ointment|ointments]] is useful to prevent [[epistaxis]] | |||
* | |||
* | |||
==References== | ==References== | ||
Revision as of 20:23, 27 October 2020
|
Epistaxis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Epistaxis medical therapy On the Web |
|
American Roentgen Ray Society Images of Epistaxis medical therapy |
|
Risk calculators and risk factors for Epistaxis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief:Amir Behzad Bagheri, M.D.
Overview
Most of the time no action is needed to stop epistaxis. In active bleeding nasal compression is the first line to stop bleeding. If bleeding continues there are other options like cautery and some vasoconstrictive agents like oxymetazoline or phenylephrine to control bleeding.
Medical Therapy
- General management of patients is important. Stabilizing the patient and treating the specific cause is the basis of management.[1] [2][3]
At first Airway , breathing and circulation should be evaluated.
If nasal bleeding is active and nasal compression couldn't stop bleeding, there are the following medical options:
- Vasoconstrictors (Use with caution in children and patients with glaucoma, HTN, peripheral vasoconstriction, cardiac diseases and cerebrovascular problems):
- Preferred regimen (1): Oxymetazoline 0.05% intranasal spray. In children <6 years just with physicians suggestion.
- Alternative regimen (1): Phenylephrine 0.25% intranasal spray. In children ≥2 years Phenylephrine 0.125% nasal solution can be used.
- Alternative regimen (2): Epinephrine 1:100,000 with Lidocaine 1% (Topical ).
- Antifibrinolytic:
- Preferred regimen (1): Tranexamic acid (TXA) (Topical ).
- Preferred regimen (1): Tranexamic acid (TXA) (Topical ).
- Chemical cauterization ( At first anesthesia bleeding site and limit nasal cautery to site:
- Preferred regimen (1): Silver nitrate 25%-75%
- Alternative regimen (1): Chromic acid
- Alternative regimen (2): Trichloroacetic acid
References
- ↑ Tunkel, David E.; Anne, Samantha; Payne, Spencer C.; Ishman, Stacey L.; Rosenfeld, Richard M.; Abramson, Peter J.; Alikhaani, Jacqueline D.; Benoit, Margo McKenna; Bercovitz, Rachel S.; Brown, Michael D.; Chernobilsky, Boris; Feldstein, David A.; Hackell, Jesse M.; Holbrook, Eric H.; Holdsworth, Sarah M.; Lin, Kenneth W.; Lind, Meredith Merz; Poetker, David M.; Riley, Charles A.; Schneider, John S.; Seidman, Michael D.; Vadlamudi, Venu; Valdez, Tulio A.; Nnacheta, Lorraine C.; Monjur, Taskin M. (2020). "Clinical Practice Guideline: Nosebleed (Epistaxis)". Otolaryngology–Head and Neck Surgery. 162 (1_suppl): S1–S38. doi:10.1177/0194599819890327. ISSN 0194-5998.
- ↑ Krempl, Greg A.; Noorily, Allen D. (2016). "Use of Oxymetazoline in the Management of Epistaxis". Annals of Otology, Rhinology & Laryngology. 104 (9): 704–706. doi:10.1177/000348949510400906. ISSN 0003-4894.
- ↑ Montastruc, François; Montastruc, Guillaume; Taudou, Marie-Josée; Olivier-Abbal, Pascale; Montastruc, Jean-Louis; Bondon-Guitton, Emmanuelle (2014). "Acute Coronary Syndrome After Nasal Spray of Oxymetazoline". Chest. 146 (6): e214–e215. doi:10.1378/chest.14-1873. ISSN 0012-3692.